Amikacin
Severe
Database
Clinical effect not specified
Source: DDInter
Drug reference
Cisatracurium
Neuromuscular Blocker
Neuromuscular Blocker
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
—
not curated
Top interactionssee all 12 →
- AmikacinSevereDatabaseDDInter
- Botulinum Toxin Type ASevereDatabaseDDInter
- Botulinum Toxin Type BSevereDatabaseDDInter
- ColistimethateSevereDatabaseDDInter
Mechanism
Cisatracurium, a non-depolarising neuromuscular blocking drug, competes with acetylcholine for receptor sites at the neuromuscular junction. Its action can be reversed with anticholinesterases.
Indications
To enable light anaesthesia with adequate relaxation of muscles of the abdomen and diaphragmTo relax vocal cords and allow tracheal tube passageTracheal intubation and mechanical ventilation in intensive care patientsLong-term neuromuscular blockadeAdjuvant in surgical anesthesia to obtain relaxation of skeletal muscleGood choice for patients with impaired renal function
Dosing
- Adult
- 0.15–0.2 mg/kg (initiation); 0.03 mg/kg (intermittent injection); 1–3 µg/kg/min (continuous infusion)
- Pediatric
- Commonly administered for short procedures where only a single intubating dose is required
- Renal adjustment
- No adjustment required; suitable for use in patients with renal impairment as duration of action is not dependent on kidney elimination.
- Hepatic adjustment
- No adjustment required; suitable for use in patients with hepatic impairment as duration of action is not dependent on liver elimination.
Pharmacokinetics
Onset
2–8 min
Duration
Slightly longer than atracurium besilate (intermediate-acting, typically 30-40 minutes); suitable for long-term neuromuscular blockade.
Protein binding
nearly 4 times more potent than atracurium
Metabolism
Undergoes non-enzymatic metabolism which is independent of liver and kidney function.
Excretion
Not dependent on hepatic or renal elimination pathways.
Side effects
Common
less histamine releasefewer side effects
Serious
- No histamine release
Drug interactions
Botulinum Toxin Type A
Severe
Database
Clinical effect not specified
Source: DDInter
Botulinum Toxin Type B
Severe
Database
Clinical effect not specified
Source: DDInter
Colistimethate
Severe
Database
Clinical effect not specified
Source: DDInter
Gentamicin
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Kanamycin
Severe
Database
Clinical effect not specified
Source: DDInter
Neomycin
Severe
Database
Clinical effect not specified
Source: DDInter
Netilmicin
Severe
Database
Clinical effect not specified
Source: DDInter
Paromomycin
Severe
Database
Clinical effect not specified
Source: DDInter
Plazomicin
Severe
Database
Clinical effect not specified
Source: DDInter
Polymyxin B
Severe
Database
Clinical effect not specified
Source: DDInter
Streptomycin
Severe
Database
Clinical effect not specified
Source: DDInter
Related guidelines
Other Neuromuscular Blocker drugs
Ask House about Cisatracurium
Continue into a citation-backed clinical answer with the drug context already attached.
Textbook-sourced·Sources: KD Tripathi 7e, Goodman & Gilman 14e, Katzung, BNF·Updated: 2026-05-10